Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitors. 2023

Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
School of Chemistry, Sun Yat-sen University, 132 Waihuan East Road, Guangzhou 510006, PR China; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, United States.

Three series of phenylurea indole derivatives were synthesized with potent inhibitory activities on ABCG2 with simple and efficient synthetic routes. Among these compounds, four phenylurea indole derivatives 3c-3f with extended π system were discovered as the most potent ABCG2 inhibitors, while these compounds showed no inhibition on ABCB1. Compounds 3c and 3f were selected for further investigation to explore the mechanisms of action on reversing ABCG2-mediated multidrug resistance (MDR). The results revealed that compounds 3c and 3f increased the accumulation of mitoxantrone (MX) in ABCG2-overexpressing cells, but they did not alter the expression level or localization of ABCG2 in cells. In addition, both 3c and 3f significantly stimulated the ATP hydrolysis of ABCG2 transporter indicating that they can be competitive substrates of ABCG2 transporter, and thereby increase the accumulation of mitoxantrone in ABCG2-overexpressing H460/MX20 cells. Both 3c and 3f was docked into the drug-binding site of the human ABCG2 transporter protein (PDB 6FFC) with high affinities. This study showed that extending the π system of phenylurea indole derivatives enhanced their inhibitory activities on ABCG2, which may provide a clue for the further research to discover more potent ABCG2 inhibitors.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010671 Phenylurea Compounds Compounds that include the amino-N-phenylamide structure. Phenylcarbamides,Phenylurea Derivatives,Compounds, Phenylurea,Derivatives, Phenylurea
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000070997 ATP Binding Cassette Transporter, Subfamily G, Member 2 ATP-binding cassette transporter, sub-family G protein that functions as a high capacity UREA exporter, transporter of STEROLS, and in the absorption and efflux of many drugs. Its efflux activity for ANTINEOPLASTIC AGENTS contributes to DRUG RESISTANCE. It functions as a homodimer and is expressed by cells in a variety of organs, as well as by NEOPLASTIC STEM CELLS. ABCG2 Protein,ABCG2 Transporter,ATP Binding Cassette Transporter, Sub-Family G, Member 2,CD338 Antigen
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D019008 Drug Resistance, Neoplasm Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures. Antibiotic Resistance, Neoplasm,Antineoplastic Drug Resistance,Drug Resistance, Antineoplastic,Antineoplastic Agent Resistance,Neoplasm Drug Resistance,Resistance, Antineoplastic Agent,Resistance, Antineoplastic Drug

Related Publications

Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
September 2017, Bioorganic & medicinal chemistry letters,
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
December 2020, European journal of medicinal chemistry,
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
July 2022, Bioorganic & medicinal chemistry,
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
November 2016, Bioorganic & medicinal chemistry,
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
January 2022, European journal of medicinal chemistry,
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
May 2007, Bioorganic & medicinal chemistry letters,
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
January 2014, Bioorganic & medicinal chemistry,
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
May 2018, Molecules (Basel, Switzerland),
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
February 2020, European journal of medicinal chemistry,
Gao-Jie Ye, and Chao-Yun Cai, and Xing-Duo Dong, and Zhuo-Xun Wu, and Qiu-Xu Teng, and Jing-Quan Wang, and Zhe-Sheng Chen, and Bo Wang
January 2020, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!